Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

520
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
520
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

299
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
299
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

364
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
364
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

436
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
436
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

652
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
652
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

437
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
437

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Vulnerability of anterior medial temporal lobe subregions to early tau-related neurodegeneration in Alzheimer's disease: Converging evidence from tau-PET and plasma p-tau217.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Effects of Task-Irrelevant Talker Identity and Continuity on Spatial Selective Attention Under Interruption.

Trends in hearing·2026
Same author

Uncovering distinct spatiotemporal trajectories of T-N mismatch subtypes with likely co-pathology in Alzheimer's disease using event-based modeling.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Medial temporal lobe Tau-Neurodegeneration mismatch from structural imaging and plasma biomarkers.

Brain : a journal of neurology·2026
Same author

Temporal Modeling of Amyloid and Tau Trajectories in Alzheimer's Disease Using PET and Plasma Biomarkers.

Annals of neurology·2026
Same author

Surface Inspection and Description in Metrology and Tribology-Vol. 2.

Materials (Basel, Switzerland)·2026
Same journal

Patient-derived forebrain cortical organoids reveal biphasic tau-MAP6-microtubule axis dysfunction in tauopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Genetic architecture of the limbic white matter microstructure in aging and Alzheimer's Disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Greater choroid plexus volume is linked to poor sleep, neurodegeneration, and cognitive deficits in older adults: Evidence from the IGNITE Study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Plasma-based neurobiological protein biomarkers as predictors of dementia progression: Insights from longitudinal aging study in India - Diagnostic assessment of dementia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Neuropathology-specific language features in primary progressive aphasia.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Dementia blood biomarkers in the context of post-stroke cognitive outcomes: Systematic review and evidence synthesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Ver todos los artículos relacionados
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Jan 7, 2026

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.4K

Manifestaciones Clínicas

Dawn Mechanic-Hamilton1, Valerie Humphreys2, Danielle Hing2

  • 1Penn Alzheimer's Disease Research Center, University of Pennsylvania, Philadelphia, PA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
Resumen
Este resumen es generado por máquina.

Este estudio piloto demuestra que la plataforma de rendimiento de aplicaciones cognitivas móviles (mCAPP) es utilizable para la evaluación cognitiva remota en pacientes con Deterioro Cognitivo Leve (DCL) o enfermedad de Alzheimer (EA) en tratamiento con terapias anti-amiloides (AAT). Los hallazgos respaldan el potencial de mCAPP para rastrear los efectos del tratamiento.

Palabras clave:
Deterioro Cognitivo LeveEnfermedad de AlzheimerTerapias Anti-amiloidesEvaluación Cognitiva RemotaPlataforma de Rendimiento de Aplicaciones Cognitivas Móviles

Más Videos Relacionados

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.7K
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

6.1K

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.4K
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.7K
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

6.1K

Área de la Ciencia:

  • Neurociencia
  • Salud Digital
  • Ensayos Clínicos

Sus antecedentes:

  • La evaluación cognitiva eficaz es crucial para el seguimiento de las enfermedades neurodegenerativas y las respuestas al tratamiento.
  • El advenimiento de las terapias anti-amiloides (AAT) requiere métodos fiables para rastrear los beneficios y riesgos del tratamiento.
  • Las evaluaciones remotas basadas en aplicaciones ofrecen una solución escalable para el seguimiento cognitivo.

Objetivo del estudio:

  • Evaluar la viabilidad y usabilidad de la plataforma de rendimiento de aplicaciones cognitivas móviles (mCAPP) para la evaluación cognitiva en el hogar.
  • Recopilar datos remotos de rendimiento cognitivo en pacientes con Deterioro Cognitivo Leve (DCL) o enfermedad de Alzheimer (EA) leve en tratamiento con AAT.
  • Evaluar la fiabilidad y validez inicial de mCAPP en comparación con las pruebas neuropsicológicas tradicionales.

Principales métodos:

  • Un estudio piloto que involucró a 11 participantes con DCL o EA leve en tratamiento con AAT.
  • Los participantes utilizaron las tareas gamificadas de mCAPP tanto en la clínica como en casa durante hasta tres meses.
  • Los datos recopilados incluyeron el uso de mCAPP, las calificaciones de usabilidad y las comparaciones con pruebas neuropsicológicas en papel y lápiz.

Principales resultados:

  • Los participantes se comprometieron consistentemente con mCAPP en casa (1-3 sesiones/semana) durante hasta 3 meses.
  • mCAPP demostró una buena usabilidad (calificación de 7.1/9) y la dificultad de la tarea fue percibida como apropiada por la mayoría de los usuarios.
  • Todas las tareas de mCAPP mostraron diferencias en el rendimiento entre las condiciones de carga cognitiva baja y alta, lo que indica sensibilidad a la carga cognitiva.

Conclusiones:

  • La plataforma de rendimiento de aplicaciones cognitivas móviles (mCAPP) es una herramienta usable para la evaluación cognitiva en clínica y en el hogar en pacientes que reciben AAT.
  • Los resultados iniciales sugieren que mCAPP tiene fiabilidad y validez para evaluar el rendimiento cognitivo en esta población.
  • La investigación futura se centrará en el análisis de datos longitudinales y los efectos de la práctica de mCAPP.